|
|||||
|
|
Pharmacokinetics of experimental pentavalent antimony after intramuscular administration in adult volunteers |
|
| Authors: | MSc Laura Vásquez MSc José V Scorza Dagert MD Nelson Vicuña-Fernández MSc Sabrina López PhD Elina Rojas PhD Belén Pérez |
| Institution: | 1 University of The Andes, Faculty of Medicine, Valera School of Medicine, Laboratory of Pharmacology, Valera, Venezuela 2 University of The Andes, Center of Parasitological Investigations, José Witremundo Torrealba, NURR, Trujillo, Venezuela 3 University of The Andes, Faculty of Sciences, Laboratory of MolecularSpectroscopy, La Hechicera, Venezuela 4 Autonomous University of Barcelona,Service of Pharmacological Analysis, Bellaterra, Barcelona, Spain |
| Abstract: | Background:Pentavalent antimony (SbV) has demonstrated therapeuticeffectiveness against clinical manifestations of leishmaniasis, an infection caused by Leishmania, a genus of flagellate protozoa comprising parasites of worldwide distribution. Approximately 1.8 million new cases are reported annually.Objective:The aim of this study was to assess the pharmacokinetics of the investigational generic SbV, Ulamina (pentachloride of antimony + N-methylglucamine), in healthy adult volunteers.Methods:In this study, SbV was administered IM as a single 5-mg/kg dose.Blood samples were collected at 0.25, 0.75, 1, 2, 4, 8, 12, and 24 hours after administration; urine samples were collected at 6-hour intervals during the 24-hour postadministration period. Determination of trivalent antimony, SbV, and total antimony concentrations in blood and urine samples was carried out using atomic absorption spectrometry. Clinical history was reviewed and the subjects were monitored before and after administration of SbV using physical examination, weight, and hepatic- and renal-function studies. The pharmacokinetic parameters calculated were Cmax, Tmax, absorption constant (Ka), elimination constant (Kel), AUC2-24h, AUC0-∞, elimination phase (t½β), volume of distribution (Vd), and urinary excretion rate.Results:Five subjects (3 men, 2 women; mean age, 28 years range, 18-34 years]) were included in the study. One hour after drug administration the following values were obtained: Cmax, 1.1 μg/mL; Tmax, 1.3 hours; Ka, 1.87 hours; Kel, 0.043 hours; AUC0-24h, 12.26 μg/mL · h; AUC0-∞, 19.84 μg/mL · h; t½β, 17.45 hours; Vd, 6.6 L/kg; and urinary excretion rate, 2.8 μg/h; these were mean values for the entire study group. The single dose was well tolerated by all subjects.Conclusions:The investigational generic SbV, Ulamina, was associated with linearelimination after IM administration of a single 5-mg/kg dose. A 2-compartment pharmacokinetic model was observed in these volunteers; the mean t½β, was 17.45 hours and the mean Vd was 6.6 L/kg. |
| Keywords: | pharmacokinetic antimony Ulamina humans antileishmania drugs |
| 本文献已被 ScienceDirect 等数据库收录！ | |